Novo Says Still Some Uncertainty on Tresiba Costs

Oct. 31 (Bloomberg) -- Novo Nordisk A/S Chief Financial Officer Jesper Brandgaard talks about the company's third-quarter profit reported today, sales forecast and the launch of its new diabetes treatment, Tresiba. He speaks from Bagsvaerd, Denmark, with Caroline Hyde on Bloomberg Television's "The Pulse." (Source: Bloomberg)